Axerion Therapeutics, Inc.is a biotechnology company that is developing disease-modifying therapeutics for the management and treatment of spinal cord injury (SCI), stroke recovery and Alzheimer's Disease.
Axerion’s Prion Protein (PrP) project is a novel potential therapeutic approach for patients suffering from Alzheimer’s disease. Axerion is developing small molecule oral compounds to block the binding of β-amyloid (Aβ) oligomers (clumps of Aβ peptides) to PrP in the brain, thereby preventing a cascade of events that result in brain dysfunction. Axerion’s technology, if successful, could help slow or halt cognitive decline in Alzheimer’s patients.
With its Nogo Receptor platform, Axerion is developing treatments that have the potential to stimulate regrowth in axons, which are long cellular fibers that electrically connect one nerve cell to another and play a vital role in supporting neurological function. These potential treatments could help to restore function in patients who are suffering from spinal cord injuries, stroke and other central nervous system disorders.